# Turn Therapeutics Inc. (TTRX) Source: https://www.quantisnow.com/company/TTRX Generated: 2026-10-31T11:05:02.275Z - Ticker: TTRX - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - SEC CIK: 0002023016 ## Latest TTRX news and filings - 2026-10-21 20:01 UTC [U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat](https://www.quantisnow.com/insight/us-bancorp-btig-to-host-turn-therapeutics-for-virtual-fireside-6753394) - 2026-10-19 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Turn Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-turn-therapeutics-inc-6750585) - 2026-10-06 23:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Turn Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-turn-therapeutics-inc-6739551) - 2026-09-10 12:10 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6710934) - 2026-09-10 12:00 UTC [Conference Announcement] [Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum](https://www.quantisnow.com/insight/turn-therapeutics-to-present-at-stifel-2026-virtual-immunology-and-6710886) - 2026-09-09 12:10 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6709376) - 2026-09-09 12:00 UTC [Leadership Update] [Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer](https://www.quantisnow.com/insight/turn-therapeutics-appoints-former-cdc-director-robert-r-redfield-md-6709309) - 2026-09-08 11:00 UTC [Leadership Update] [NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director](https://www.quantisnow.com/insight/novabridge-appoints-martin-dewhurst-to-board-of-directors-as-an-6707354) - 2026-08-26 20:42 UTC [SEC Form D] [SEC Form D filed by Turn Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-turn-therapeutics-inc-6695823) - 2026-08-18 12:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Turn Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-turn-therapeutics-inc-6686020) - 2026-08-17 20:14 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6685024) - 2026-08-12 20:50 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Turn Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-turn-therapeutics-inc-6678379) - 2026-08-12 20:40 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6678287) - 2026-08-12 20:30 UTC [Leadership Update] [Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/turn-therapeutics-provides-corporate-updates-and-reports-second-quarter-2026-6678168) - 2026-07-28 12:05 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6650753) - 2026-07-28 12:01 UTC [Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026](https://www.quantisnow.com/insight/turn-therapeutics-to-ring-the-nasdaq-closing-bell-on-monday-6650731) - 2026-07-07 12:05 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6629513) - 2026-07-07 12:05 UTC [Earnings Date] [Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis](https://www.quantisnow.com/insight/turn-therapeutics-announces-final-stage-2-design-and-data-driven-expansion-6629508) - 2026-07-06 20:01 UTC [Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis](https://www.quantisnow.com/insight/turn-therapeutics-to-host-webcast-presenting-comprehensive-interim-analysis-and-6627951) - 2026-06-08 21:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Dewhurst Martin William](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dewhurst-martin-william-6593992) - 2026-06-08 21:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Gengos Andrew](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gengos-andrew-6593991) - 2026-06-08 21:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Golden Arthur F](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-golden-arthur-f-6593990) - 2026-06-08 21:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Kester Kent Edward](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kester-kent-edward-6593988) - 2026-06-03 10:12 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6585679) - 2026-06-01 22:06 UTC [SEC Form 4] [Chief Executive Officer Burnam Bradley Evan received a gift of 600,000 shares and gifted 600,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-burnam-bradley-evan-received-a-gift-of-6582601) - 2026-06-01 12:45 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6580878) - 2026-06-01 12:30 UTC [Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis](https://www.quantisnow.com/insight/turn-therapeutics-reports-interim-analysis-findings-and-adaptive-optimization-strategy-6580809) - 2026-05-27 12:10 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6573947) - 2026-05-27 12:05 UTC [Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model](https://www.quantisnow.com/insight/turn-therapeutics-announces-peer-reviewed-publication-in-journal-of-dermatological-treatment-6573934) - 2026-05-19 12:15 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6561770) - 2026-05-19 12:01 UTC [Conference Announcement] [Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026](https://www.quantisnow.com/insight/turn-therapeutics-to-present-at-jefferies-global-healthcare-conference-2026-6561735) - 2026-05-18 12:15 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6559245) - 2026-05-18 12:05 UTC [Leadership Update] [Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead](https://www.quantisnow.com/insight/turn-therapeutics-appoints-physician-scientist-and-former-fda-commissioner-dr-stephen-6559225) - 2026-05-13 01:33 UTC [SEC Form C-TR filed by Turn Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-c-tr-filed-by-turn-therapeutics-inc-6549415) - 2026-05-11 20:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Turn Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-turn-therapeutics-inc-6545138) - 2026-05-11 20:10 UTC [SEC Form 8-K] [Turn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/turn-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6544948) - 2026-05-11 20:05 UTC [Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates](https://www.quantisnow.com/insight/turn-therapeutics-reports-first-quarter-2026-financial-results-and-provides-6544720) - 2026-04-03 12:09 UTC [SEC Form 4] [SEC Form 4 filed by Burnam Bradley Evan](https://www.quantisnow.com/insight/sec-form-4-filed-by-burnam-bradley-evan-6486696) - 2026-04-03 12:08 UTC [SEC Form 4] [SEC Form 4 filed by Golden Arthur F](https://www.quantisnow.com/insight/sec-form-4-filed-by-golden-arthur-f-6486694) - 2026-04-03 12:07 UTC [SEC Form 4] [SEC Form 4 filed by Burnam Bradley Evan](https://www.quantisnow.com/insight/sec-form-4-filed-by-burnam-bradley-evan-6486692) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TTRX - RSS and alerts for TTRX: https://www.quantisnow.com/docs/rss-feeds.md